EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY Egyptian International Pharmaceutical Industries Company Share Price
Equities
PHAR
EGS38081C013
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.81 EGP | -3.17% |
|
-7.05% | +14.55% |
| Sales 2024 * | 6.18B 129M 10.78B | Sales 2025 * | 7.59B 159M 13.23B | Capitalization | 6.22B 130M 10.84B |
|---|---|---|---|---|---|
| Net income 2024 * | 874M 18.27M 1.52B | Net income 2025 * | 1.08B 22.68M 1.89B | EV / Sales 2024 * | 1.84 x |
| Net Debt 2024 * | 5.16B 108M 8.99B | Net Debt 2025 * | 5.31B 111M 9.26B | EV / Sales 2025 * | 1.52 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
4.19% | Yield 2025 * |
5.98% | Free-Float | 45.47% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.17% | ||
| 1 week | -7.05% | ||
| Current month | -5.43% | ||
| 1 month | -12.11% | ||
| 3 months | +6.63% | ||
| 6 months | +10.32% | ||
| Current year | +14.55% |
1 week
41.41
45.89
1 month
41.4148.00
Current year
37.0053.49
1 year
24.5053.49
3 years
24.5053.49
5 years
24.5083.73
10 years
24.50122.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Chief Executive Officer | - | - | |
| Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 41.81 | -3.17% | 561,319 |
| 23/24/23 | 43.18 | -4.11% | 317,979 |
| 22/24/22 | 45.03 | +0.74% | 369,365 |
| 21/24/21 | 44.7 | -0.62% | 232,521 |
| 18/24/18 | 44.98 | -3.79% | 740,477 |
End-of-day quote Egyptian Exchange, April 24, 2024
More quotes
Egyptian International Pharmaceuticals Industries Co SAE (EIPICO) specializes in manufacturing and marketing pharmaceutical products. The products include primarily antibiotics, vitamins, anesthetics and analgesics, drugs for eye care, treatment of rheumatism, gout, gastrointestinal, dermatological and cardiovascular diseases, and are administered as capsules, gels and effervescent tablets.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
41.81
EGP
Average target price
72.2
EGP
Spread / Average Target
+72.69%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +14.55% | 130M | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- PHAR Stock
